现任领导
首页  研究院概况  现任领导
  • 储以微

    博士,教授,博士生导师
    邮箱:ywchu@shmu.edu.cn
    验室主页:http://brc.fudan.edu.cn



工作经历
分党委书记,复旦大学生物医学研究院(2014.03-今)
研究生院副院长,复旦大学(2012.10-2014.02)
医学学位与研究生教育管理办公室主任,复旦大学(2011.05-2014.02)
党委副书记,复旦大学上海医学院(2007.06-2012.07)

系主任,复旦大学基础医学院免疫学系(2013.06-今)
中心主任,复旦大学生物治疗研究中心(2010.11-今)
教授,复旦大学基础医学院免疫学系(2007.04-今)
访问学者,美国EACRI癌症研究中心(2003.7- 2004.5)(1997.2-1998.8)
博士后,美国华盛顿大学西雅图(1995.11-1997.2)

副理事长,中国免疫学会(2019-今)                               
副理事长,上海市免疫学会(2014-今)
教育经历
博士,复旦大学免疫学系(2002-2006)
硕士,上海医科大学免疫学系(1991-1994)
学士,上海医科大学临床医学系(1983-1989)
所获人才项目
曙光学者 上海市 2004
所获奖项
上海市自然科学奖二等奖(第一完成人),2020
上海医学科奖三等奖(第一完成人),2020
上海医学科技奖一等奖(第一完成人),2019
上海市第31届优秀发明奖(第一完成人),2019
宝钢教育基金会优秀教师奖,2019
钟扬式好老师,2019
上海市教学成果二等奖(第一完成人),2018
复旦大学教学成果一等奖(第一完成人),2017
《医学免疫学》上海市高校精品课程(负责人),2016
《免疫学》教育部首批英语授课品牌课程(负责人),2013
研究方向
长期从事肿瘤免疫与免疫生物治疗,炎癌转化的免疫学机制研究,以及B淋巴细胞与免疫调节。在肿瘤放化疗后体内免疫系统重建及机制、TLRs抗肿瘤免疫效应及机制研究、以及肿瘤疫苗和CART设计等方面取得系列发现,研发了快速DC疫苗、第四代CART细胞免疫治疗技术。主持和参与多项国家和省部级项目,包括国家自然科学基金重点项目、面上项目、国家重点研发计划、上海市自然科学重点项目等。在国内外学术刊物上发表论文270篇,申请或授权专利10余项。主编规划教材《免疫学与病原生物学》,《医学免疫学》,以及人卫出版社英文教材《Medical Immunology》等。
代表论文

1.Wang Z#, Lu Z#, Lin S#, Xia J, Zhong Z, Xie Z, Xing Y, Qie J, Jiao M, Li Y, Wen H, Zhao P, Zhang D, Zhou P, Qian J, Luo F, Wang L, Yu H, Liu J, Gu J, Liu R*, Chu Y*. Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion. Immunity. 2022; 55(6):1067-1081.e8.

2.Lu Z#, Liu R#, Wang Y#, Jiao M#, Li Z, Wang Z, Huang C, Shi G, Ke A, Wang L, Fu Y, Xia J, Wen H, Zhou J, Wang X, Ye D, Fan J*, Chu Y*, Cai J*. Ten-eleven translocation-2 inactivation restrains IL-10-producing regμLatory B cells to enable antitumor immunity in hepatocellμLar carcinoma. Hepatology. 2022; doi: 10.1002/hep.32442.

3.Yuedi Wang , Yiyuan Gao , Congyi Niu , Bo Wang , Shushu Zhao , Gils Roex , Jiawen Qian , Jingbo Qie , Lin Chen , Chenhe Yi , Sébastien Anguille , Jie Liu* , Feifei Luo* , Yiwei Chu *. Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor.Cancer Immunol Immunother. 2022 Apr 19. doi: 10.1007/s00262-022-03195-4.

4.Luman Wang , Damo Xu , Yiwei Chu* . Editorial: Insights into Regulatory B Cells. Front Immunol.2022 Apr 25;13:903711. doi: 10.3389/fimmu.2022.903711.

5.Ying Fu, Luman Wang, Baichao Yu, Damo Xu * , Yiwei Chu *. Immunometabolism shapes B cell fate and functions. Immunology. 2022 Aug;166(4):444-457. doi: 10.1111/imm.13499.

6.Wanwei Zheng #, Huan Song #, Zhongguang Luo #, Hao Wu #, Lin Chen , Yuedi Wang , Haoshu Cui , Yufei Zhang , Bangting Wang , Wenshuai Li , Yao Liu , Jun Zhang , Yiwei Chu *, Feifei Luo *, Jie Liu *. Acetylcholine ameliorates colitis by promoting IL-10 secretion of monocytic myeloid-derived suppressor cells through the nAChR/ERK pathway. PNAS .March 16, 2021,118 (11) e2017762118.

7.Liu J, Li Y, Lu Z, Gu J, Liang Y, Huang E, Wang Z, Zhang H, Wang L, Zhang D, Yu H, Liu R, Chu Y*. Deceleration of glycometabolism impedes IgG-producing B cell-mediated tumor elimination by targeting SATB1. Immunology. 2019 Jan;156(1):56-68.

8.Qian J#, Wang C#, Wang B, Yang J, Wang Y, Luo F, Xu J, Zhao C, Liu R, Chu Y*.The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 2018 Oct 17;15(1):290.

9.Yao Y#, Luo F#, Tang C#, Chen D#, Qin Z, Hua W, Xu M, Zhong P, Yu S, Chen D, Ding X, Zhang Y, Zheng X, Yang J, Qian J, Deng Y, Hoon DSB, Hu J, Chu Y*, Zhou L*. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother. 2018 Nov;67(11):1777-1788.

10.Qian J, Luo F, Yang J, Liu J, Liu R, Wang L, Wang C, Deng Y, Lu Z, Wang Y, Lu M, Wang JY, Chu Y*.TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia. Cancer Immunol Research. 2018 Oct;6(10):1220-1233.

11.Wang Z, Zhang H, Liu R, Qian T, Liu J, Huang E, Lu Z, Zhao C, Wang L*,Chu Y*.Peyer's patches-derived CD11b+ B cells recruit regulatory T cells through CXCL9 in dextran sulphate sodium-induced colitis. Immunology. 2018 Nov;155(3):356-366.

12.Liu R, Lu Z, Gu J, Liu J, Huang E, Liu X, Wang L, Yang J, Deng Y, Qian J, Luo F, Wang Z, Zhang H, Jiang X, Zhang D, Qian J, Liu G, Zhu H, Qian Y, Liu Z, Chu Y*. MicroRNAs 15A and 16-1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. Gastroenterology. 2018 Feb;154(3):637-651.

13.Lu Z, Liu J, Liu X, Huang E, Yang J, Qian J, Zhang D, Liu R, Chu Y*. MiR-15a/16-1 Suppresses AHR-dependent IL-22 Secretion in CD4+ T cells and Contributes to Immune-mediated Organ Injury. Hepatology. 2018 Mar;67(3):1027-1040.

14.Wang Y, Luo F, Yang J, Zhao C,Chu Y*.New Chimeric Antigen Receptor Design for Solid Tumors. Front Immunol. 2017 Dec 22;8:1934.

15.Yang J, Liu R, Deng Y, Qian J, Lu Z, Wang Y, Zhang D, Luo F, Chu Y*.MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting mTOR. Int J Cancer. 2017 Nov 15;141(10):2082-2092.

16.Luo F, Qian J, Yang J, Deng Y, Zheng X, Liu J, Chu Y* (corresponding). Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Research. 2016 Jul;26(7):850-3.

17.Liu X,Jiang X, Liu R, Wang L, Qian T, Zheng Y, Deng Y, Huang E, Xu F, Chu Y*.B cells expressing CD11b effectively inhibit CD4+ T cell responses and ameliorate experimental autoimmune hepatitis in mice. Hepatology. 2015 Nov;62(5):1563-75.

18.L Wang, A Ray, X Jiang, J-y Wang, S Basu, X Liu, T Qian, R He, BN Dittel and Y Chu *.T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis .Mucosal Immunology. 2015 Nov;8(6):1297-312.

19.Ronghua Liu, Jie Gu, Pei Jiang, Yijie Zheng, Xiaoming Liu, Xuechao Jiang , Enyu Huang, Shudao Xiong,Fengkai Xu, Guangwei Liu, Di Ge, Yiwei Chu*. DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clinical Cancer Research, 2015;21(4):854-63.

20.Zhang, Feifei Luo, Yuchan Cai, Nan Liu, Luman Wang, Damo Xu and Chu Yiwei *. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. Journal of Immunology. 2011, 186(4): 1963-9.Faculty of 1000


Top